Marginal Zone B-Cell Lymphoma
10
1
1
5
Key Insights
Highlights
Success Rate
63% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
30.0%
3 terminated out of 10 trials
62.5%
-24.1% vs benchmark
0%
0 trials in Phase 3/4
120%
6 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 5 completed trials
Clinical Trials (10)
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases
Bendamustine Plus Rituximab (BR) for Relapsed or Progressive Marginal Zone B-cell Lymphoma (MZBCL)
UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep
Combination Therapy Using Lenalidomide (Revlimid)- Low Dose Dexamethasone and Rituximab for Treatment of Rituximab-Resistant, Non-Aggressive B-Cell Lymphomas
Bendamustine and Rituximab for the Treatment of Splenic Marginal Zone Lymphoma
Adoptive TReg Cell for Suppression of aGVHD After UCB HSCT for Heme Malignancies
T-Regulatory Cell and CD3 Depleted Double Umbilical Cord Blood Transplantation in Hematologic Malignancies
A Phase II Study of Doxycycline in Relapsed NHL
Multicenter Phase II Study to Evaluate the Clinical Activity and the Safety Profile of Everolimus in Marginal Zone B-cell Lymphomas (MZL)